Artículo especial
¿Se ha de asumir el efecto de clase farmacológica entre los diferentes análogos de la hormona liberadora de la hormona luteinizante usados en el tratamiento del carcinoma de próstata?
Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?
a Unidad de Oncología Radioterápica, Instituto de Medicina Oncológica y Molecular de Asturias, Asturias, España
b Servicio de Oncología Radioterápica, Hospital General Vall d′Hebrón, Barcelona, España
c Servicio de Oncología Radioterápica, Complejo Hospitalario Universitario de Albacete, Albacete, España
Leído
3583
Vecesse ha leído el artículo
879
Total PDF
2704
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 0 | 2 | 2 |
| 2025 10 | 0 | 2 | 2 |
| 2025 9 | 0 | 2 | 2 |
| 2025 8 | 0 | 4 | 4 |
| 2025 7 | 0 | 3 | 3 |
| 2025 6 | 0 | 1 | 1 |
| 2025 5 | 0 | 2 | 2 |
| 2025 4 | 0 | 3 | 3 |
| 2025 3 | 0 | 3 | 3 |
| 2025 1 | 0 | 4 | 4 |
| 2024 12 | 0 | 4 | 4 |
| 2024 11 | 0 | 3 | 3 |
| 2024 10 | 0 | 5 | 5 |
| 2024 9 | 0 | 14 | 14 |
| 2024 8 | 0 | 6 | 6 |
| 2024 7 | 0 | 2 | 2 |
| 2024 6 | 0 | 2 | 2 |
| 2024 4 | 0 | 2 | 2 |
| 2024 3 | 0 | 5 | 5 |
| 2024 2 | 0 | 8 | 8 |
| 2024 1 | 0 | 3 | 3 |
| 2023 12 | 0 | 1 | 1 |
| 2023 11 | 0 | 5 | 5 |
| 2023 10 | 0 | 2 | 2 |
| 2023 9 | 0 | 4 | 4 |
| 2023 8 | 0 | 8 | 8 |
| 2023 7 | 0 | 3 | 3 |
| 2023 6 | 0 | 5 | 5 |
| 2023 5 | 0 | 5 | 5 |
| 2023 4 | 0 | 3 | 3 |
| 2023 3 | 1 | 8 | 9 |
| 2023 2 | 0 | 6 | 6 |
| 2022 1 | 0 | 6 | 6 |
| 2022 12 | 0 | 5 | 5 |
| 2022 11 | 0 | 5 | 5 |
| 2022 10 | 0 | 1 | 1 |
| 2022 9 | 0 | 6 | 6 |
| 2022 8 | 0 | 3 | 3 |
| 2022 5 | 0 | 6 | 6 |
| 2021 12 | 0 | 3 | 3 |
| 2021 11 | 0 | 1 | 1 |
| 2021 9 | 0 | 1 | 1 |
| 2021 8 | 0 | 2 | 2 |
| 2021 7 | 0 | 4 | 4 |
| 2021 6 | 1 | 4 | 5 |
| 2021 3 | 0 | 1 | 1 |
| 2021 2 | 0 | 2 | 2 |
| 2020 1 | 0 | 1 | 1 |
| 2020 9 | 0 | 1 | 1 |
| 2020 7 | 0 | 1 | 1 |
| 2020 4 | 0 | 1 | 1 |
| 2020 3 | 0 | 1 | 1 |
| 2019 12 | 0 | 1 | 1 |
| 2019 9 | 0 | 1 | 1 |
| 2019 6 | 0 | 1 | 1 |
| 2019 5 | 0 | 8 | 8 |
| 2018 8 | 1 | 0 | 1 |
| 2018 2 | 17 | 4 | 21 |
| 2018 1 | 17 | 3 | 20 |
| 2017 12 | 23 | 2 | 25 |
| 2017 11 | 13 | 0 | 13 |
| 2017 10 | 14 | 5 | 19 |
| 2017 9 | 17 | 2 | 19 |
| 2017 8 | 13 | 7 | 20 |
| 2017 7 | 16 | 5 | 21 |
| 2017 6 | 13 | 8 | 21 |
| 2017 5 | 19 | 7 | 26 |
| 2017 4 | 27 | 7 | 34 |
| 2017 3 | 17 | 98 | 115 |
| 2017 2 | 9 | 10 | 19 |
| 2016 1 | 11 | 3 | 14 |
| 2016 12 | 32 | 15 | 47 |
| 2016 11 | 46 | 18 | 64 |
| 2016 10 | 41 | 19 | 60 |
| 2016 9 | 49 | 9 | 58 |
| 2016 8 | 33 | 9 | 42 |
| 2016 7 | 37 | 3 | 40 |
| 2016 6 | 37 | 24 | 61 |
| 2016 5 | 32 | 35 | 67 |
| 2016 4 | 43 | 30 | 73 |
| 2016 3 | 26 | 20 | 46 |
| 2016 2 | 18 | 28 | 46 |
| 2015 1 | 29 | 26 | 55 |
| 2015 12 | 22 | 19 | 41 |
| 2015 11 | 27 | 17 | 44 |
| 2015 10 | 32 | 18 | 50 |
| 2015 9 | 20 | 12 | 32 |
| 2015 8 | 42 | 9 | 51 |
| 2015 7 | 39 | 9 | 48 |
| 2015 6 | 24 | 4 | 28 |
| 2015 5 | 36 | 12 | 48 |
| 2015 4 | 36 | 17 | 53 |
| 2015 3 | 22 | 13 | 35 |
| 2015 2 | 19 | 9 | 28 |
| 2015 1 | 31 | 8 | 39 |
| 2014 12 | 44 | 12 | 56 |
| 2014 11 | 41 | 13 | 54 |
| 2014 10 | 55 | 16 | 71 |
| 2014 9 | 42 | 5 | 47 |
| 2014 8 | 46 | 7 | 53 |
| 2014 7 | 36 | 7 | 43 |
| 2014 6 | 48 | 10 | 58 |
| 2014 5 | 37 | 4 | 41 |
| 2014 4 | 26 | 10 | 36 |
| 2014 3 | 29 | 8 | 37 |
| 2014 2 | 18 | 9 | 27 |
| 2014 1 | 28 | 4 | 32 |
| 2013 12 | 24 | 2 | 26 |
| 2013 11 | 21 | 4 | 25 |
| 2013 10 | 28 | 14 | 42 |
| 2013 9 | 19 | 5 | 24 |
| 2013 8 | 17 | 6 | 23 |
| 2013 7 | 10 | 3 | 13 |
| 2010 9 | 1133 | 0 | 1133 |
Mostrar todo
